News | October 15, 2007

Defibrillation Leads Suspension Underscores Need for Guidelines

October 16, 2007 — In response to Medtronic’s decision to voluntarily suspend its Sprint Fidelis defibrillation leads, the Heart Rhythm Society (HRS) made a statement to underscore the importance of the society’s task force recommendations for the surveillance, analysis and performance reporting of pacemakers and implantable cardioverter defibrillators (ICDs).

A 15-member task force of leading cardiac care providers and experts developed the guidelines with feedback from regulators at the FDA, representatives from industry and patient advocacy groups. Additional feedback was received from a public comment period that ended May 30, 2006.

“Our guidelines are intended to help ensure transparency and promote cooperation among manufacturers, physicians, patients and the FDA,” said Bruce D. Lindsay, M.D., FHRS, president of the Heart Rhythm Society. “Adhering to the principles of these guidelines can help ensure the best patient care possible.”

The overarching objectives of the HRS recommendations include the following:
• Greater transparency in the post-market surveillance, analysis and reporting of information;
• The establishment of new systems to identify malfunctioning devices more quickly;
• Standard notification and communication to physicians and patients from the manufacturer when a device malfunction is identified. Manufacturers, the FDA and physicians are encouraged to work together to prevent adverse events due to device malfunctions; and
• The global scope of device performance issues; cooperation among industry, physicians, government authorities and national health care systems are necessary to reduce the risk of injuries and deaths due to device malfunctions.

Specific recommendations and more information are available online at: http://www.hrsonline.org/Policy/ClinicalGuidelines/HRS-Device-Perform-Recs.cfm.

For more information: www.HRSonline.org

Related Content

Feature | Implantable Cardioverter Defibrillator (ICD) | By Dave Fornell, Editor

February 2, 2020 — The U.S. Food and Drug Administration (FDA) has identified a recent recall of the Boston Scientific ...

Home February 02, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

January 8, 2020 — A new study published this week in HeartRhythm, the journal of the Heart Rhythm Society (HRS), found ...

Home January 08, 2021
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 8, 2020 — Final results from the UNTOUCHED study of the Emblem Subcutaneous Implantable Defibrillator (S-ICD) System ...

Home May 08, 2020
Home
Feature | Implantable Cardioverter Defibrillator (ICD)

May 8, 2020 — A new clinical trial is the first to compare the safety and efficacy of subcutaneous implantable ...

Home May 08, 2020
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 11, 2019 — Medtronic plc announced the start of a worldwide pivotal study evaluating its investigational ...

Home October 11, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

September 18, 2019 — Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention ...

Home September 18, 2019
Home
Feature | Implantable Cardioverter Defibrillator (ICD) | Dave Fornell, Editor

This is a brief overview of updates on implantable cardioverter defibrillators (ICD), including new technology ...

Home May 24, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of the ...

Home May 13, 2019
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 9, 2018 — Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable ...

Home August 09, 2018
Home
Feature | Implantable Cardioverter Defibrillator (ICD)

July 11, 2018 — Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and ...

Home July 11, 2018
Home
Subscribe Now